1. Home
  2. Q vs INCY Comparison

Q vs INCY Comparison

Compare Q & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Qnity Electronics Inc.

Q

Qnity Electronics Inc.

SELL

Current Price

$114.91

Market Cap

26.4B

Sector

Technology

ML Signal

SELL

Logo Incyte Corp.

INCY

Incyte Corp.

SELL

Current Price

$119.86

Market Cap

24.5B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
Q
INCY
Founded
2024
1991
Country
United States
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Commercial Physical & Biological Resarch
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
26.4B
24.5B
IPO Year
2025
1994

Fundamental Metrics

Financial Performance
Metric
Q
INCY
Price
$114.91
$119.86
Analyst Decision
Strong Buy
Buy
Analyst Count
10
28
Target Price
★ $173.30
$132.25
AVG Volume (30 Days)
★ 1.9M
1.6M
Earning Date
11-04-2026
10-29-2026
Dividend Yield
★ 0.27%
N/A
EPS Growth
N/A
★ 4173.33
EPS
★ 2.18
0.50
Revenue
★ $4,754,000,000.00
$3,394,635,000.00
Revenue This Year
$22.21
$17.74
Revenue Next Year
$11.89
$4.22
P/E Ratio
★ $54.41
$242.04
Revenue Growth
9.67
★ 13.67
52 Week Low
$72.81
$89.25
52 Week High
$177.28
$132.60

Technical Indicators

Market Signals
Indicator
Q
INCY
Relative Strength Index (RSI) 44.61 52.58
Support Level $108.06 $115.38
Resistance Level $123.10 $130.53
Average True Range (ATR) 5.87 3.97
MACD 0.28 0.41
Stochastic Oscillator 30.31 70.81

Price Performance

Historical Comparison
Q
INCY

About Q Qnity Electronics Inc.

Qnity is a specialty chemicals company created in 2025 after being spun off from DuPont. It sells chemicals and materials to the semiconductor industry, which generates the majority of sales, and also the electronics industry. Qnity specializes in materials science, including supplying key materials required to manufacture semiconductors and interconnected devices.

About INCY Incyte Corp.

Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.

Share on Social Networks: